



AUS BIO LIMITED
ACN 091 858 114

AUS BIO LIMITED (“Company”) gives notice that the Annual General Meeting of the Company will be held as a Virtual Meeting on Thursday 18th November 2021 at 11.00am. The Link for the Virtual Meeting is <https://agm.link/ablu21>

ORDINARY BUSINESS

1. Receipt of Reports

To receive and consider the financial report of the Company and the reports of the directors and auditor for the year ended 30 June 2021.

2. Re-election of Mr Charles Farquharson

To elect in accordance with rule 8 of the Company’s constitution, Mr Charles Farquharson, who retires by rotation and, being eligible, offers himself for re-election.

3. Re-election of Dr Peter James Jenkins

To elect in accordance with rule 8 of the Company’s constitution, Dr Peter James Jenkins, who retires by rotation and, being eligible, offers himself for re-election.

4. Other Business

To consider any other business brought forward in accordance with the Company’s constitution or the law.

Signed:

By order of the Board
Peter Jenkins
Executive Director
Date 21st October 2021

NOTES

These notes form part of the notice of annual general meeting.

Shareholders Entitled to Vote

The directors have determined that, for the purpose of voting at the meeting, shareholders are those persons who are the registered holders of shares at 11.00 am on Tuesday 16th November 2021.

Proxies and Corporate Representatives

A member who is entitled to vote at this meeting may appoint a proxy who need not be a member of the Company. For the convenience of members, a proxy appointment form is enclosed.

To record a valid vote, shareholders will need to complete and lodge the Proxy Form (and the power of attorney or other authority (if any) under which it is signed, or a certified copy of it) at the share register of the Company, Link Market Services Limited. Please complete and forward the Proxy Form to Link Market Services Limited.

- By post at the following address:
Link Market Services Limited
Locked Bag A14, Sydney South, NSW 1235

OR

- By facsimile on:
+61 2 9287 0309

OR

- Online at www.linkmarketservices.com.au

So that it is received by no later than 11.00 am on Tuesday 16th November 2021.

A member which is a body corporate, or a body corporate which is appointed as a proxy, may appoint an individual as its representative to exercise any of the powers the body may exercise at meetings of the Company's shareholders. The appointment may be a standing one. Unless the appointment states otherwise, the representative may exercise all of the powers that the appointing body could exercise at a meeting or in voting a resolution.

The representative should bring to the meeting evidence of his or her appointment, including any authority under which the appointment is signed, unless it has previously been given to the Company.

EXPLANATION STATEMENT

This explanatory statement forms part of the notice of annual general meeting. The main purpose of this explanatory statement is to provide shareholders with information concerning all of the resolutions proposed in the notice of annual general meeting.

Item 1 – Receipt of Reports

The Company's financial report and the reports of the directors and auditor for the year ending for 30th June 2021 have been mailed to shareholders to allow shareholders to ask questions relating to these documents.

Item 2 – Re-election of Mr Charles Farquharson

Mr Charles Farquharson, B. Com (Melb). SF FIN Mr Farquharson has been a Director since the date of incorporation of the company on 3 March 2000. Mr Farquharson has been involved in stockbroking for over 50 years. In 1970, he joined the partnership of A.C. Goode & Co. and became a member of the Australian Stock Exchange. More recently, he was Vice President of Merrill Lynch Private (Australia) and a Senior Investment advisor at Morgans Financial Limited until his retirement from stockbroking on 30 June 2017. He has had many years' experience dealing with "small to mid-cap" companies including equity raisings and management issues

Recommendation

The Directors with Mr Charles Farquharson abstaining, recommend that shareholders vote in favour of Mr Farquharson's re-election.

Item 3 – Re-election of Dr Peter James Jenkins

Dr Peter J. Jenkins, M.B. B.S., F.R.A.C.P. – Executive Director, Management Dr Jenkins has been a Director since the date of incorporation of the Company on 3 March 2000. Dr Jenkins is a consultant physician and gastroenterologist and has held or holds both clinical research positions within the Alfred Hospital and also the Baker Medical Research Institute, Melbourne. He has held the positions of Head, Clinical Business Unit Gastroenterology and Gastrointestinal Surgery and Clinical Dean at the Alfred Hospital for the Monash University Faculty of Medicine. He is also a past Chairman of the Committee of Chairman Senior Medical Staffs of Major Victorian Hospitals. Dr Jenkins has been a Director of a number of private and public biotechnology companies, including the ASX listed Starpharma Limited where he was Deputy Chairman before his retirement (in 2015) after 17 years as a Director. He is a former Director and Chairman of Immuron (formerly Anadis Limited). Dr Jenkins is a former judge of the Australian Technology Awards. He is experienced in the issues and problems that face early-stage biomedical research and development companies in Australia.

Recommendation

The Directors with Dr Peter James Jenkins abstaining, recommend that shareholders vote in favour of Dr Jenkin's re-election

All other information reasonably required by Shareholders

The Directors believe that this notice contains all other information known by the Company and the Directors that is reasonably required by Shareholders in order to decide whether or not it is in the Company's interest to vote in favour of the resolutions.